Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: RBS Into Profit But Sets Aside GBP400 Million For Forex Probe

Fri, 31st Oct 2014 09:23

LONDON (Alliance News) - Royal Bank of Scotland Group PLC Friday reported a swing to third-quarter pretax profit, but results included hundreds of millions of pounds of litigation and conduct costs, relating to matters such as regulators' probe into the foreign exchange markets and a further charge taken for the payment protection insurance scandal.

In a statement, RBS, which is 80%-owned by the UK government, said it made a GBP1.27 billion pretax profit in the quarter ended September 30, compared with a GBP634 million pretax loss in the corresponding quarter last year.

The quarterly performance was supported by net impairment provision releases of GBP801 million, primarily in Ulster Bank and in RBS Capital Resolution, the 'bad bank' it set up to run down capital intensive assets, as RBS benefits from improving economic conditions in the UK and Ireland.

"UK and Ireland are showing signs of growth, and impairment trends are significantly better than we had anticipated at the start of the year," Chief Executive Ross McEwan said in a statement.

However, revenue fell to GBP4.36 billion from GBP4.89 billion, as a rise in net interest income, the difference between what RBS receives in interest on loans and the interest it pays out to savers, was more than offset by a drop in non-interest income.

The quarterly performance was achieved despite the bank setting aside GBP780 million relating to litigation and conduct costs, including GBP400 million for regulators' investigations into alleged manipulation in the foreign exchange market and a further GBP100 million for PPI due to higher-than-expected "reactive" complaint volumes. The PPI mis-selling scandal has now cost RBS more than GBP3.3 billion.

The provisions followed a similar move by rival lender Barclays PLC, which on Thursday made a further GBP170 million provision for PPI and set aside GBP500 million for the foreign exchange probe. On Tuesday, Lloyds Banking Group PLC set aside a further GBP900 million to cover PPI expectations.

McEwan also said RBS is on track to meet its capital targets, with the bank's common equity tier 1 ratio improving by 220 basis points since the year end and 70 basis points in the quarter to 10.8%. RBS is working towards a common equity tier 1 ratio minimum of 12%. In a conference call with journalists, McEwan said RBS is focused on further strengthening its capital position.

"We shouldn't be thinking about dividends until we've got a really good capital build and got some of the bumps in the road out of the way," McEwan said.

RBS's leverage ratio, a simple unweighted ratio of a bank?s equity to a measure of its total un-risk-weighted exposure, designed to guard against weaknesses in banks' ability to model risk, increased to 3.9% from 3.7% over the course of the quarter. The bank has a medium term target of attaining a leverage ratio of between 3.5% and 4.0%, while wanting to maintain a ratio of at least 4.0% in the long-term.

The UK banking sector is awaiting proposals over the leverage ratio at 1400 GMT, when the UK Financial Policy Committee?s review of the leverage ratio will be released. Although the Basel Committee on Banking Supervision has set a provisional leverage ratio of 3%, UK banks could face stricter rules.

"In February I placed trust at the heart of my new strategy for our bank. We have taken the first steps towards that goal, with early progress in making RBS simpler, clearer and fairer," Chief Executive McEwan said in a statement.

RBS also confirmed it will retain control of Ulster Bank, following a strategic review.

"We have confirmed today that Ulster Bank remains a core part of our bank. We have a good market position and believe that, with investment, Ulster Bank can deliver attractive shareholder returns in the future," McEwan said.

However, he also noted the banking group's "long list of conduct and litigation issues" to deal with, adding that RBS has "much, much more to do" to restore our customers' trust.

Those issues include an ongoing investigation being undertaken by UK regulators into an IT crash in 2012 that resulted in considerable delays to customer accounts and payments.

RBS also confirmed it has appointed external headhunters as it seeks a replacement for Chairman Philip Hampton, who will leave the bank during 2015 in order to join GlaxoSmithKline PLC.

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.